{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:07Z","timestamp":1783318507204,"version":"3.54.6"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NO. 81873283\u8054\u7cfb\u7535\u8bdd:021 - 8873283"],"award-info":[{"award-number":["NO. 81873283\u8054\u7cfb\u7535\u8bdd:021 - 8873283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bone marrow metastasis (BMM) is an adverse prognostic factor in advanced breast cancer and may cause severe myelosuppression, particularly refractory thrombocytopenia, thereby limiting systemic therapy. Sacituzumab tirumotecan (sac-TMT) is a Trop-2-directed antibody-drug conjugate (ADC), but evidence for its use in patients with severe thrombocytopenia and compromised bone marrow reserve remains limited. We report a real-world case of sac-TMT use in this challenging clinical setting and discuss relevant considerations regarding ADC resistance and treatment sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>\n                      A 62-year-old postmenopausal woman (BMI: 16.23\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), with hypertension, hyperlipidemia, and no known family history of hereditary disease, was diagnosed in March 2015 with HR+\/HER2 \u2212 breast cancer (pT1N2M0). She underwent right mastectomy with axillary dissection and immediate latissimus dorsi flap reconstruction, followed by four cycles of TC chemotherapy, adjuvant radiotherapy, and 6\u00a0years of tamoxifen. She relapsed in July 2021 with multiple bone metastases; after multiple lines of endocrine therapy and CDK4\/6 inhibitors, her disease progressed. In September 2024 she was diagnosed with bone marrow metastases accompanied by severe refractory thrombocytopenia (nadir 12 \u00d7 10^9\/L), unresponsive to conventional platelet-promoting therapies. In December 2024, sac-TMT was initiated together with platelet-supportive measures; during therapy platelets stabilized at \u226550 \u00d7 10^9\/L, with no grade \u22653 non-hematologic adverse events, and disease stability exceeded 8 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sac-TMT combined with intensive hematologic supportive care was feasible in this heavily pretreated HR+\/HER2 \u2212 breast cancer patient with BMM-induced refractory thrombocytopenia. Platelet stabilization, reduced transfusion dependence, and clinical disease stability were observed before PET-CT-confirmed progression. Further case series and prospective studies are needed to validate the feasibility and safety of this approach in similar high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1854219","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:07Z","timestamp":1783316227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab tirumotecan in an advanced HR+\/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Han","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwei","family":"Gao","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Dou","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Ying","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairu","family":"Mao","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.annonc.2023.09.3111","article-title":"ctDNA as a predictive biomarker in advanced breast cancer: lessons from the MONALEESA studies","volume":"34","author":"Agostinetto","year":"2023","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e87118","DOI":"10.7759\/cureus.87118","article-title":"Stabilization of symptomatic bone marrow metastases in breast cancer: a case report of two patients treated with trastuzumab deruxtecan","volume":"17","author":"Alevizopoulos","year":"2025","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/jco.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2-and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.18632\/oncotarget.27766","article-title":"Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer","volume":"11","author":"Cardillo","year":"2020","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/1389202924666230726112233","article-title":"Trop-2 as an actionable biomarker in breast cancer","volume":"24","author":"Cursano","year":"2023","journal-title":"Curr. Genomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14737140.2024.2392775","article-title":"Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer","volume":"24","author":"Garrigos","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/cancers15041130","article-title":"Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies","volume":"50","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/tbcr-24-40","article-title":"Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion","volume":"5","author":"Huang","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17588359251326710","DOI":"10.1177\/17588359251326710","article-title":"Clinician's guide: expert insights on the use of CDK4\/6 inhibitors in patients with early breast cancer","volume":"17","author":"Hussain","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21037\/tbcr-24-50","article-title":"Trastuzumab deruxtecan in patients with bone metastases from HR+\/HER2-low breast cancer: efficacy enhanced by denosumab","volume":"6","author":"Irelli","year":"2025","journal-title":"Transl. Breast Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11523-024-01036-1","article-title":"Sacituzumab govitecan: a review in unresectable or metastatic HR+\/HER2- breast cancer","volume":"19","author":"Kang","year":"2024","journal-title":"Target Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2024.180","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17588359251396656","DOI":"10.1177\/17588359251396656","article-title":"Current landscape of sequencing ADCs in metastatic breast cancer","volume":"17","author":"McLaughlin","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104721","DOI":"10.1016\/j.breast.2026.104721","article-title":"Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States","volume":"86","author":"Modi","year":"2026","journal-title":"Breast"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/biom14101219","article-title":"Molecular targets for breast cancer therapy","volume":"14","author":"Montazeri Aliabadi","year":"2024","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s13256-024-04922-4","article-title":"First-line endocrine therapy combined with CDK 4\/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report","volume":"18","author":"Pangarsa","year":"2024","journal-title":"J. Med. Case Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.26574\/maedica.2018.13.3.238","article-title":"Hormonal treatment for symptomatic bone marrow metastasis in breast cancer patients","volume":"13","author":"Rahmat","year":"2018","journal-title":"Maedica (Bucur)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2-metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1781533","DOI":"10.3389\/or.2026.1781533","article-title":"Sacituzumab tirumotecan (sac-TMT\/MK-2870\/SKB264): a novel antibody-drug conjugate in breast cancer","volume":"20","author":"Sofianidi","year":"2026","journal-title":"Oncol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"Npj Breast Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tbcr-24-15","article-title":"Expert consensus on the clinical application of immunotherapy in breast cancer: 2024","volume":"5","author":"Wang","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00432-008-0503-2","article-title":"Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples","volume":"135","author":"Xiao","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1042773","DOI":"10.3389\/fonc.2022.1042773","article-title":"Symptomatic bone marrow metastases in breast cancer: a retrospective cohort study","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1390361","DOI":"10.3389\/fphar.2024.1390361","article-title":"Mechanism and clinical progression of solid tumors bone marrow metastasis","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15330338231184990","DOI":"10.1177\/15330338231184990","article-title":"Clinical features and prognosis of uncommon metastatic breast cancer: a retrospective analysis of 82 cases","volume":"22","author":"Zhang","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"26717","DOI":"10.1038\/s41598-025-12883-x","article-title":"Patterns and prognostic implications of distant metastasis in breast cancer based on SEER population data","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:08Z","timestamp":1783316228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1854219"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1854219","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1854219"}}